BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017By Nasdaq OMXSep 25, 2017, 12:30 PM UTC
BusinessMadrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial HypercholesterolemiaBy Nasdaq OMXSep 19, 2017, 11:30 AM UTC
BusinessGalectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02By Nasdaq OMXSep 12, 2017, 12:30 PM UTC
BusinessClarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 18, 2017, 12:30 PM UTC
BusinessImmuron Commences US Non-Deal Institutional Investor RoadshowBy Nasdaq OMXAug 15, 2017, 1:15 PM UTC
BusinessMadrigal Pharmaceuticals Reports 2017 Second Quarter Financial ResultsBy Nasdaq OMXAug 10, 2017, 12:50 PM UTC
BusinessMadrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASHBy Nasdaq OMXAug 1, 2017, 11:30 AM UTC
BusinessGalectin Therapeutics to Present at the Singular Research Summer ConferenceBy Nasdaq OMXJul 7, 2017, 4:00 PM UTC
